Canada Drug Delivery Devices Market Outlook to 2023-Central Venous Catheters, Infusion Systems, Needle Free Injections and Metered Dose Inhaler Devices
Region:North America
Product Code:GDMEMC0255DB
August 2017
165
About the Report
Canada Drug Delivery Devices Market Outlook to 2023-Central Venous Catheters, Infusion Systems, Needle Free Injections and Metered Dose Inhaler Devices
Summary
GlobalData's new report, "Canada Drug Delivery Devices Market Outlook to 2023", provides key market data on the Canada Drug Delivery Devices market. The report provides value, in millions of US dollars and volume (in units) within market categories-Central Venous Catheters, Needle Free Injections, Infusion Systems and Metered Dose Inhaler Devices.
The report also provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants. Based on the availability of data for the particular market and country, information related to pipeline products, news and deals is available in the report.
Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.
Scope
Market size and company share data for Drug Delivery Devices market categories-Central Venous Catheters, Needle Free Injections, Infusion Systems and Metered Dose Inhaler Devices.
Annualized market revenues (USD million) and volume (units) data for each of the market categories. Data is provided from 2009 to 2016 and forecast to 2023.
2016 company shares and distribution shares data for each of the market categories.
Global corporate-level profiles of key companies operating within the Canada Drug Delivery Devices market.
Key players covered include GlaxoSmithKline Plc, AstraZeneca Plc, Hospira Inc, Becton Dickinson and Co, Boehringer Ingelheim GmbH, Baxter International Inc, Medtronic plc and others.
Reasons to buy
Develop business strategies by identifying the key market categories poised for strong growth in the future.
Develop market-entry and market expansion strategies.
Design competition strategies by identifying who-stands-where in the market.
Develop investment strategies by identifying the key market categories expected to register strong growth in the near future.
What are the key distribution channels and what's the most preferred mode of product distribution-Identify, understand and capitalize.
Scope of the Report
Products
Companies
GlaxoSmithKline Plc
Hospira Inc
Becton Dickinson and Co
AstraZeneca Plc
Baxter International Inc
Medtronic Plc
Boehringer Ingelheim GmbH
Pfizer Inc
Merck & Co Inc
Fresenius Kabi AG
Glenmark Pharmaceuticals Ltd
Table of Contents
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 7
2 Introduction 9
2.1 What Is This Report About? 9
2.2 Drug Delivery Devices Market Segmentation 9
2.3 Definitions of Markets Covered in the Report 10
3 Drug Delivery Devices Market, Canada 13
3.1 Drug Delivery Devices Market, Canada, Revenue ($m), 2009-2023 13
3.2 Drug Delivery Devices Market, Canada, Revenue Mix ($m), 2016 15
3.3 Drug Delivery Devices Market, Canada, Category Contribution by Revenue ($m), 2016 16
3.4 Drug Delivery Devices Market, Canada, Category Comparison by Revenue ($m), 2009-2023 17
3.5 Drug Delivery Devices Market, Canada, Revenue ($m), 2009-2016 18
3.6 Drug Delivery Devices Market, Canada, Revenue ($m), 2016-2023 20
3.7 Drug Delivery Devices Market, Canada, Volume (Units), 2009-2023 22
3.8 Drug Delivery Devices Market, Canada, Volume (Units), 2009-2016 23
3.9 Drug Delivery Devices Market, Canada, Volume (Units), 2016-2023 25
3.10 Drug Delivery Devices Market, Canada, Company Share by Revenue ($m), 2016 27
4 Central Venous Catheters Market, Canada 29
4.1 Central Venous Catheters Market, Canada, Revenue Mix ($m), 2016 29
4.2 Central Venous Catheters Market, Canada, Segment Contribution (%), 2016 30
4.3 Central Venous Catheters Market, Canada, Revenue ($m), 2009-2016 31
4.4 Central Venous Catheters Market, Canada, Revenue ($m), 2016-2023 33
4.5 Central Venous Catheters Market, Canada, Volume (Units), 2009-2016 35
4.6 Central Venous Catheters Market, Canada, Volume (Units), 2016-2023 37
4.7 Central Venous Catheters Market, Canada, Distribution Share by Revenue ($m), 2015-2016 39
4.8 Central Venous Catheters Market, Canada, Company Share by Revenue ($m), 2016 40
5 Infusion Systems Market, Canada 42
5.1 Infusion Systems Market, Canada, Revenue Mix ($m), 2016 42
5.2 Infusion Systems Market, Canada, Segment Contribution (%), 2016 43
5.3 Infusion Systems Market, Canada, Revenue ($m), 2009-2016 45
5.4 Infusion Systems Market, Canada, Revenue ($m), 2016-2023 47
5.4.1 Ambulatory Infusion Pumps Market, Canada, Revenue ($m), by Segment, 2009-2016 49
5.4.2 Syringe Pumps Market, Canada, Revenue ($m), by Segment, 2009-2016 51
5.4.3 Ambulatory Infusion Pumps Market, Canada, Revenue ($m), by Segment, 2016-2023 53
5.4.4 Syringe Pumps Market, Canada, Revenue ($m), by Segment, 2016-2023 55
5.5 Infusion Systems Market, Canada, Volume (Units), 2009-2016 57
5.6 Infusion Systems Market, Canada, Volume (Units), 2016-2023 59
5.6.1 Ambulatory Infusion Pumps Market, Canada, Volume (Units), by Segment, 2009-2016 61
5.6.2 Syringe Pumps Market, Canada, Volume (Units), by Segment, 2009-2016 63
5.6.3 Ambulatory Infusion Pumps Market, Canada, Volume (Units), by Segment, 2016-2023 65
5.6.4 Syringe Pumps Market, Canada, Volume (Units), by Segment, 2016-2023 67
5.7 Infusion Systems Market, Canada, Distribution Share by Revenue ($m), 2015-2016 69
5.8 Infusion Systems Market, Canada, Company Share by Revenue ($m), 2016 70
6 Infusion Systems Market, Canada 72
6.1 Needle Free Injections Market, Canada, Revenue ($m), 2009-2016 72
6.2 Needle Free Injections Market, Canada, Revenue ($m), 2016-2023 73
6.3 Needle Free Injections Market, Canada, Volume (Units), 2009-2016 74
6.4 Needle Free Injections Market, Canada, Volume (Units), 2016-2023 75
6.5 Needle Free Injections Market, Canada, Distribution Share by Revenue ($m), 2015-2016 76
6.6 Needle Free Injections Market, Canada, Company Share by Revenue ($m), 2016 77
7 Metered Dose Inhaler Devices Market, Canada 79
7.1 Metered Dose Inhaler Devices Market, Canada, Revenue ($m), 2009-2016 79
7.2 Metered Dose Inhaler Devices Market, Canada, Revenue ($m), 2016-2023 80
7.3 Metered Dose Inhaler Devices Market, Canada, Volume (Units), 2009-2016 81
7.4 Metered Dose Inhaler Devices Market, Canada, Volume (Units), 2016-2023 82
7.5 Metered Dose Inhaler Devices Market, Canada, Distribution Share by Revenue ($m), 2015-2016 83
7.6 Metered Dose Inhaler Devices Market, Canada, Company Share by Revenue ($m), 2016 84
8 Overview of Key Companies in Canada, Drug Delivery Devices Market 86
8.1 GlaxoSmithKline Plc 86
8.1.1 Company Overview 86
8.2 Hospira Inc 86
8.2.1 Company Overview 86
8.3 Becton Dickinson and Co 86
8.3.1 Company Overview 86
8.4 AstraZeneca Plc 86
8.4.1 Company Overview 86
8.5 Baxter International Inc 87
8.5.1 Company Overview 87
8.6 Medtronic Plc 87
8.6.1 Company Overview 87
8.7 Boehringer Ingelheim GmbH 87
8.7.1 Company Overview 87
8.8 Pfizer Inc 88
8.8.1 Company Overview 88
8.9 Merck & Co Inc 88
8.9.1 Company Overview 88
8.10 Fresenius Kabi AG 88
8.10.1 Company Overview 88
8.11 Glenmark Pharmaceuticals Ltd 89
8.11.1 Company Overview 89
9 Drug Delivery Devices Market Pipeline Products 90
10 Financial Deals Landscape 96
10.1 Acquisition 96
10.1.1 Teleflex Acquires Pyng Medical 96
10.2 Asset Transactions 98
10.2.1 ICU Medical Acquires Hospira Infusion Systems Business from Pfizer 98
10.3 Equity Offerings 100
10.3.1 InMed Pharma Raises USD4.3 Million in Public Offering of Units 100
10.3.2 Aequus Pharma Raises USD3.9 Million in Public Offering of Units 102
10.3.3 RepliCel Life Sciences Raises USD2 Million in Private Placement of Units 104
10.3.4 RepliCel Life Sciences Raises USD0.3 Million in Private Placement of Units 106
10.3.5 Tetra Bio-Pharma Raises USD0.8 Million in Private Placement of Units 107
10.3.6 RepliCel Life Sciences Raises USD3.3 Million in Private Placement of Units 108
10.3.7 Aequus Pharma Raises USD2 Million in Public Offering of Shares 109
10.4 Partnerships 111
10.4.1 Vetter Pharma International and Microdermics Enter into Agreement 111
10.4.2 United Therapeutics Enters into Licensing Agreement with Respira Therapeutics 112
10.4.3 CannaRoyalty Enters into Licensing Agreement with NuTrae 113
10.4.4 Aequus Pharma to Enter into Licensing Agreement with Transdermal Research Pharm Labs 114
10.4.5 Valeant Pharma Enters into Licensing Agreement with EyeGate Pharma 115
10.4.6 Hikma Pharma Enters into Licensing Agreement with Orion 117
10.4.7 Pfizer Terminates its Licensing Agreement with pSivida 118
10.4.8 Bayer Enters into Licensing Agreement with DelSiTech 119
10.4.9 BioCorRx Enters into Licensing Agreement with Therakine 120
10.5 Venture Financing 121
10.5.1 Microdermics Raises USD1 Million in Venture Financing 121
10.5.2 Microdermics Secures Venture Funding 122
11 Recent Developments 123
11.1 Corporate Communications 123
11.1.1 Jun 14, 2017: Tetra Bio-Pharma Appoints Aphria CFO, Mr. Carl Merton to the Board of Directors 123
11.1.2 Jun 01, 2017: Novelion Therapeutics Appoints John J. Orloff, M.D., to Its Board of Directors, Steps Down as EVP, Head of R&D 123
11.1.3 May 30, 2017: Tetra Bio-Pharma Strengthens its Board with the Appointment of Dr. Bill Cheliak 123
11.1.4 May 10, 2017: Tetra Bio-Pharma Strengthens Management Team 124
11.1.5 Apr 24, 2017: Tetra Bio-Pharma Accelerates Sales Strategy with the Appointment of Denis Courchesne as Vice President, Sales 124
11.1.6 Mar 31, 2017: Novelion Therapeutics Appoints Mark Corrigan, M.D. to Board of Directors 125
11.1.7 Mar 27, 2017: Tetra Bio-Pharma Appoints Edward Miller as Vice President, Investor Relations & Corporate Communications 125
11.1.8 Feb 03, 2017: RepliCel Appoints Corporate Executive, Hugh Rogers to its Board of Directors 125
11.1.9 Jan 25, 2017: Yutaka Niihara, MD, MPH, CEO of Emmaus Appointed Executive Chairman of Generex Biotechnology 126
11.1.10 Nov 16, 2016: Nuvo Pharmaceuticals appoints new president 126
11.1.11 Nov 16, 2016: Nuvo Pharmaceuticals Appoints Jesse Ledger as President 127
11.1.12 Sep 01, 2016: Nuvo Pharmaceuticals Appoints New Chief Financial Officer 127
11.1.13 Jul 22, 2016: Aequus Appoints Ann Fehr as Chief Financial Officer 127
11.2 Financial Announcements 128
11.2.1 May 30, 2017: Aequus Provides First Quarter 2017 Financial Highlights 128
11.2.2 May 25, 2017: BioSyent Releases Q1 2017 Results 129
11.2.3 May 10, 2017: Nuvo Pharmaceuticals Announces 2017 First Quarter Results 129
11.2.4 May 09, 2017: Novelion Therapeutics Reports First Quarter 2017 Financial Results 131
11.2.5 May 01, 2017: Aequus Provides Fourth Quarter and Fiscal 2016 Financial Highlights 133
11.2.6 Mar 28, 2017: Intelgenx Reports Fourth Quarter And Full-Year 2016 Financial Results 134
11.2.7 Mar 15, 2017: Novelion Therapeutics Reports Preliminary Fourth Quarter & Full Year 2016 Financial Results 135
11.2.8 Mar 15, 2017: BioSyent Releases Results for Fourth Quarter and Full Year 2016 137
11.2.9 Mar 01, 2017: Nuvo Pharmaceuticals Announces 2016 Year-End and Fourth Quarter Results 138
11.2.10 Feb 28, 2017: Pyng Medical Reports First Quarter Fiscal 2017 Results 140
11.2.11 Jan 10, 2017: Pyng Medical Reports Fiscal 2016 Financial Results 141
11.2.12 Jan 09, 2017: Novelion Therapeutics Reports Preliminary 2016 Net Product Sales and Provides 2017 Outlook 141
11.2.13 Nov 30, 2016: Aequus Provides Q3 2016 Financial Highlights With Substantial Increase in Quarter Over Quarter Revenues 142
11.2.14 Nov 23, 2016: BioSyent Releases Results for Third Quarter and First Nine Months of 2016 143
11.2.15 Nov 10, 2016: Nuvo Pharmaceuticals Announces 2016 Third Quarter Results 144
11.2.16 Nov 01, 2016: QLT Announces Third Quarter 2016 Results 146
11.2.17 Oct 03, 2016: Proteocyte Diagnostics launches Straticyte to US market at AAOMS Annual Meeting 147
11.2.18 Aug 23, 2016: Pyng Medical Reports Third Quarter Fiscal 2016 Results 149
11.2.19 Aug 12, 2016: BioSyent Releases Q2 and H1 2016 Results 149
11.2.20 Aug 10, 2016: Nuvo Pharmaceuticals Announces 2016 Second Quarter Results 150
11.2.21 Aug 09, 2016: QLT Announces Second Quarter 2016 Results 151
11.3 Legal And Regulatory 153
11.3.1 Apr 19, 2017: Novelion Therapeutics’ Request to Voluntarily Delist from the Toronto Stock Exchange Granted 153
11.4 Other Significant Developments 153
11.4.1 Jun 15, 2017: Trudell Medical International: Providing patient-focused solutions and reducing health system costs: our journey in the global fight against COPD 153
11.4.2 Jun 01, 2017: Aequus Pharmaceuticals and CDRD Announce Research Collaboration to Improve Cannabinoid-Based Therapeutics 155
11.4.3 Apr 27, 2017: Pendant Biosciences Announces Acceptance into JLABS Toronto 155
11.4.4 Apr 13, 2017: PreveCeutical Signs Letter of Intent for Research & Development for Cannabinoid and Diabetes Products with UniQuest 156
11.4.5 Jan 05, 2017: RepliCel CEO Provides 2017 Forecast 157
11.4.6 Oct 20, 2016: JDRF and the University of Toronto support research into a skin patch to prevent common, life-threatening risk of T1D 159
11.4.7 Aug 30, 2016: Aequus Provides Corporate Update on Commercial and Development Programs 159
11.5 Product News 161
11.5.1 Jul 12, 2017: Intelgenx Presents at BIT's 7th Annual International Symposium of Drug Delivery Systems 161
11.5.2 Nov 12, 2016: Teleflex nasal spray syringe devices recalled; may fail to deliver full dose of medication 162
11.6 Strategy And Business Planning 162
11.6.1 May 25, 2017: RepliCel CEO Provides Company Outlook 162
11.6.2 Jan 31, 2017: CrossLife Awarded NIH SBIR Grant to Point of Care Detection of Zika virus 163
11.6.3 Oct 06, 2016: Precision NanoSystems New Headquarters Designed to Enhance Product and Service Offerings to Customers Developing Novel Nanomedicines 163
12 Appendix 165
12.1 Research Methodology 166
12.1.1 Coverage 166
12.1.2 Secondary Research 166
12.1.3 Primary Research 167
12.1.4 Company Share Analysis 167
12.1.5 Distribution Share Analysis 167
12.1.6 Benchmarking 168
12.2 GlobalData Consulting 168
12.3 Contact Us 169
12.4 Disclaimer 169
Research Methodology
Why Buy From Us?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.